Novartis Slides as Pharma Sector Softens
$Novartis AG(NVS)$
“ −4.1 % earnings pullback: Novartis faces mild sell-off as European pharma sector softens ahead of guidance update ”
Market Recap (as of Oct 28 2025)
Novartis (NVS) ended Monday down –0.94 % to $129.14, with extended-hours trading showing a sharper –3.10 % drop to $124.96 after cautious pre-earnings positioning.
The stock traded within $127.08 – $130.17, closing below the intraday VWAP ≈ $129.6, reflecting light defensive rotation ahead of its Q3 earnings call (9 a.m. ET).
Despite resilient core-drug performance (Cosentyx, Kisqali), investors shifted focus toward FX-translation losses and slowing growth in the Sandoz generic arm, weighing on sentiment across the European pharma complex.
Technical Outlook
RSI (14) ≈ 29.6 → deeply oversold; potential mean-reversion zone.
MACD (12, 26) → bearish crossover in progress, yet histogram flattening suggests selling momentum waning.
EMA 20 ≈ EMA 50 → compression phase detected after multi-session decline, setting up for volatility post-earnings.
Multiple MacdLE (+2) signals clustered at $127 – $128 on the chart → accumulation attempt near major support.
Intraday pressure remained persistent until late-session stabilization at $127.6 with a 20.6 K volume spike marking capitulation.
Breakout confirmation above $130.5 would signal recovery momentum; a drop below $127 could expose the $124 gap area.
Support / Resistance Levels
Support: $127 / $124 / $120
Resistance: $130.5 / $132.0 / $135.0
Valuation & Fundamentals
Market Cap: ≈ $250.8 B
P/E (TTM): 18.83 ×
EPS (TTM): $6.86
Dividend Yield: 3.99 % (annualized ≈ $5.15 per ADR)
Beta (5 Y): 0.57 → low volatility defensive profile
52-Week Range: $96.1 – $133.6
1-Year Target Est.: $125.35
Novartis remains fundamentally strong with solid free-cash-flow generation and a dividend near 4 %. Management’s commentary on pipeline products like Pluvicto, Scemblix, and Kisqali will drive post-call sentiment. Investors will watch for clarity on 2026 margin recovery and FX hedging initiatives given the Swiss-franc tailwind risk.
1-Week Scenario Matrix
Base case: Earnings inline → range $127 – $130 stabilization.
Bull case: EPS > $1.80 + FX headwind contained → rally to $132 – $134.
Bear case: weak guidance / currency drag → pullback to $124 support.
Signal Interpretation
RSI ≈ 29 → oversold setup ripe for short-covering; MACD flattening → momentum loss slowing; EMA compression → potential snap-reversal post-earnings. Data verified from Yahoo Finance & TradingView (Oct 28 2025 09:17 UTC).
For informational and technical-analysis purposes only; not investment advice.
For SG users only, a tool to boost your purchasing power and trading ideas with a Cash Boost Account!
Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
